Anti-Transferrin Receptor siRNA Conjugates for DM1 Uptake and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNAi therapies for muscle dystrophy, such as DM1, face challenges with poor intracellular uptake, limited blood stability, and non-specific immune stimulation, hindering their effectiveness in treating the disease.
Innovation Solution
Development of polynucleic acid molecule conjugates comprising an anti-transferrin receptor antibody or antigen binding fragment conjugated to a polynucleic acid molecule that hybridizes to the DMPK gene, optimized with specific modifications and linkers to enhance intracellular uptake, stability, and target specificity, thereby mediating effective RNA interference against DMPK.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNAi therapies are administered for muscle dystrophy treatment, then gene suppression effect is achieved, but intracellular uptake is poor
Solution Approach 1:
The patent creates a composite structure by conjugating siRNA molecules to transferrin receptor antibodies, forming an antibody-siRNA conjugate. This composite material combines the gene silencing capability of siRNA with the cell-targeting and uptake enhancement properties of the antibody, thereby improving intracellular delivery while maintaining gene suppression efficacy.
Solution Approach 2:
The transferrin receptor antibody serves as an intermediary that mediates the delivery of siRNA into cells. The antibody binds to cell surface receptors (transferrin receptors) and facilitates endocytosis, acting as a bridge that transports the siRNA payload across the cell membrane barrier, thus enhancing intracellular uptake without compromising the therapeutic effect.
2Reliability
If RNAi therapies are administered for muscle dystrophy treatment, then gene suppression effect is achieved, but blood stability is limited
Solution Approach 1:
The antibody-siRNA conjugate forms a stable composite structure where the antibody protects the siRNA from nucleases and degradation in the bloodstream. This composite material exhibits enhanced blood stability compared to free siRNA, while maintaining the gene suppression function once internalized by target cells.
Solution Approach 2:
The antibody component provides beforehand protection to the siRNA molecule against degradation by nucleases and other blood-borne factors. This protective cushioning occurs before the siRNA reaches its target, ensuring that the therapeutic molecule remains intact and functional during circulation.
3Reliability
If RNAi therapies are administered for muscle dystrophy treatment, then gene suppression effect is achieved, but non-specific immune stimulation occurs
Solution Approach 1:
The transferrin receptor antibody acts as a targeted delivery vehicle that directs siRNA specifically to cells expressing transferrin receptors (such as muscle cells in DM1). This targeted approach reduces non-specific distribution to immune cells and other tissues, thereby minimizing off-target immune stimulation while preserving the desired gene suppression effect in target tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates significantly reduce DMPK mRNA expression by at least 50-70%, effectively modulating muscle atrophy and treating myotonic dystrophy type 1 (DM1) with enhanced stability and reduced immune response.
Implementation Method 1
a polynucleic acid molecule that hybridizes to a target sequence of DMPK
Implementation Method 2
an anti-transferrin receptor antibody or antigen binding fragment thereof conjugated to a polynucleic acid molecule
Data Source
AI summary
Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).